It promotes the synthesis and release of dopamine in the striatum, reduces the reuptake of dopamine by nerve cells, and has an anti-acetylcholine effect, thereby improving the symptoms of Parkinson's disease patients.

A mild peripheral vasodilator with lipid-lowering effects; its vasodilatory effect is milder and more lasting than that of niacin, without side effects such as flushing and stomach discomfort; it selectively dilates blood vessels in diseased areas and sensitive areas stimulated by cold; it has the effects of dissolving blood clots, anti-coagulation, resisting fatty liver, and reducing capillary fragility.

It is produced after hydrolysis in the body and has lipid-lowering and vasodilation effects.

It is produced after hydrolysis in the body and has auxiliary lipid-lowering and other metabolic regulatory effects.

It is a mild peripheral vasodilator, which has the pharmacological effects of both niacin and inositol, and has lipid-lowering effects. Its vasodilatory effect is milder and more lasting than that of niacin, and it does not have the side effects of flushing and stomach discomfort after taking niacin. It can selectively dilate the blood vessels of the lesion site and the sensitive site stimulated by cold, while the dilation effect on normal blood vessels is weaker. In addition, it has the effects of dissolving blood clots, anticoagulation, anti-fatty liver, and reducing capillary fragility.

This product is a mild peripheral vasodilator, which is gradually hydrolyzed into niacin and inositol in the body, so it has the pharmacological effects of both niacin and inositol, and has lipid-lowering effects. Its vasodilating effect is milder and more lasting than that of niacin, and it does not have side effects such as flushing and stomach discomfort after taking niacin. This product can selectively dilate blood vessels in lesions and sensitive areas stimulated by cold, while its dilating effect on normal blood vessels is weaker. In addition, it has the effects of dissolving blood clots, anticoagulation, anti-fatty liver, and reducing capillary fragility. Toxicology This product is hydrolyzed into niacin and inositol in the body, among which the LD50 of niacin is 7g/kg (oral) for rats and 5g/kg (subcutaneous) for rats.

It is produced after hydrolysis in the body and participates in lipid-lowering and vasodilation effects.

It is produced after hydrolysis in the body and participates in lipid-lowering and other metabolic regulation effects.

This product belongs to the macrolide antibiotics. It inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome of sensitive bacteria. It has antibacterial activity against Staphylococcus (except methicillin-resistant strains), all groups of streptococci and Gram-positive bacilli. Streptococcus pyogenes, group A hemolytic streptococci, Staphylococcus, Streptococcus pneumoniae, meningococci, gonorrhea, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial effects on various anaerobic bacteria except Bacteroides fragilis and Fusobacterium. It also has inhibitory effects on Mycoplasma pneumoniae, Chlamydia, Legionella, Treponema pallidum, Leptospira, and Campylobacter fetus. Non-clinical toxicology studies: In long-term (2-year) studies on rats, there is no evidence of carcinogenicity or gene mutation after oral administration of erythromycin; studies on male and female rats.